LYEL ▲ +4.1% - Lyell Immunopharma, Inc.
$LYEL - Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04-NOV-2026 09:01 AM ET
Share this post
More filings for $LYEL
LYEL ▲ +4.1% - Lyell Immunopharma, Inc.Nov 4, 2026LYEL ▲ +0.1% - Lyell Immunopharma, Inc.Nov 2, 2026LYEL ▼ -5.3% - Lyell Immunopharma, Inc.Sep 10, 2026LYEL - Lyell Immunopharma, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$LYEL SEC Filing Update (18-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 18, 2026
View full $LYEL filing history →💬 Comments
Loading comments…
Leave a comment